Trafford Clarke

CIK: 0001958857

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TRAW

Traws Pharma, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TRAW
Traws Pharma, Inc.
Jul 9, 2026
Award(A)
Stock Option (right to buy)
Direct
14.2K shares-
TRAW
Traws Pharma, Inc.
Mar 8, 2026
Award(A)
Stock Option (right to buy)
Direct
33.4K shares-
TRAW
Traws Pharma, Inc.
Dec 12, 2025
Award(A)
Direct
6.2K shares-
TRAW
Traws Pharma, Inc.
Oct 12, 2025
Award(A)
Stock Option (right to purchase)
Direct
11.5K shares-
TRAW
Traws Pharma, Inc.
Jun 19, 2025
Award(A)
Stock Option (right to purchase)
Direct
23K shares-

		Type	Shares	Price		Ownership
Jul 9, 2026	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to buy)	14,150	-	-	Direct
Mar 8, 2026	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to buy)	33,435	-	-	Direct
Dec 12, 2025	TRAW Traws Pharma, Inc.	Award(A)	6,157	-	-	Direct
Oct 12, 2025	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to purchase)	11,530	-	-	Direct
Jun 19, 2025	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to purchase)	23,000	-	-	Direct

1-5 of 5 transactions

About Clarke Trafford

Clarke Trafford (SEC CIK 0001958857) files insider reports with the SEC as Director of Traws Pharma, Inc. (TRAW).

Signal8 holds 5 ownership filings by Clarke Trafford, all Form 4s, filed between Jun 23, 2025 and Jul 14, 2026. Those filings report 5 transactions, from Jun 19, 2025 to Jul 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Clarke Trafford's filings is in NEWTOWN, PA.

Recent filings by Clarke Trafford

Jul 9, 2026: Grant or award of TRAW derivative securities (Form 4, code A).
Mar 8, 2026: Grant or award of TRAW derivative securities (Form 4, code A).
Dec 12, 2025: Grant or award of TRAW shares (Form 4, code A).
Oct 12, 2025: Grant or award of TRAW derivative securities (Form 4, code A).
Jun 19, 2025: Grant or award of TRAW derivative securities (Form 4, code A).

Other insiders filing for Traws Pharma, Inc. (TRAW)

Pauza Charles David, Chief Science Officer Virology
CAUTREELS WERNER, Director
Savchuk Nikolay, Chief Operating Officer
STOVER JACK E, Director
Dukes Iain D., Chief Executive Officer
Redfield Robert, Chief Medical Officer

How to read Form 4 transaction codes